218 citations
,
January 2013 in “The Lancet Oncology” This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.
16 citations
,
October 2012 in “British Journal of Dermatology” Chemotherapy can cause significant hair thinning and changes in hair texture, while tamoxifen has a smaller effect.
5 citations
,
August 2012 in “Journal of Dermatology” This report presents a case where female pattern hair loss might be linked to tamoxifen use, with increased androgen receptor expression observed in the affected scalp area.
12 citations
,
May 2012 in “Journal of Biomedical Optics” In this study, Trichoscan®, reflectance confocal microscopy, and optical coherence tomography were found to be reliable noninvasive tools for measuring hair growth and follicle analysis after hair removal.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
103 citations
,
December 2011 in “Journal of the American Academy of Dermatology” This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.
64 citations
,
July 2011 in “Dermatologic Therapy” This review discusses treatments for chemotherapy-induced alopecia, highlighting scalp cooling for hair loss prevention and 2% topical minoxidil for regrowth acceleration as effective options, but reports a need for more rigorous trials to validate promising new therapies.
27 citations
,
June 2011 in “Journal of Advanced Nursing” The research observed that a penguin cap scalp cooling system may effectively reduce chemotherapy-induced alopecia, though its success varies due to individual characteristics and treatment regimens.
151 citations
,
August 2010 in “British Journal of Dermatology” This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.
67 citations
,
May 2010 in “Journal of The American Academy of Dermatology” This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.
73 citations
,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” This article reviews various diagnostic tools for hair disorders, describing methods ranging from invasive to noninvasive, but reports no new research findings or clinical results.
155 citations
,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” This review covers various strategies to manage chemotherapy-induced alopecia, highlighting that agents like AS101 and minoxidil can reduce its severity but not prevent it, with no new clinical results reported.
28 citations
,
January 2007 in “Dermatology” This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.
53 citations
,
January 2007 in “Dermatology” This study suggests that chemotherapy-induced anagen effluvium represents patterned hair loss, with most patients retaining hairlines, but patterns do not vary significantly by age, symptoms, or chemotherapy type.
97 citations
,
September 2006 in “Pharmaceutical Research” This review discusses advances in protecting against chemotherapy-induced alopecia and reports no new clinical results; calcitriol and cyclosporine A emerged as promising agents in animal models with broader efficacy across multiple chemotherapy drugs.
115 citations
,
September 2005 in “International Journal of Dermatology” Different ethnic groups have unique hair growth patterns, with African hair growing slower and less dense, Asian hair growing fast but sparse, and Caucasian hair being densest; men are more likely to experience hair loss than women.
47 citations
,
July 2005 in “British Journal of Dermatology” This study found no protective effect of topical calcipotriol on hair loss in chemotherapy patients, and the authors propose the term "atrophic telogen effluvium" for this type of hair loss.
159 citations
,
September 2001 in “European Journal of Cancer Care” This literature study reviews the consequences of hair loss due to chemotherapy and nursing care interventions but reports no new clinical results.
19 citations
,
June 2001 in “Annals of Internal Medicine” This case report describes total alopecia in a 53-year-old woman after 13 months of tamoxifen treatment for breast cancer, with normal hair distribution maintained elsewhere.
109 citations
,
December 1998 in “The Journal of Dermatology” This review discusses the hair follicle cycle's complex regulation and highlights the potential for targeting catagen control in future therapies without presenting new experimental data.
15 citations
,
May 1997 in “Annals of Internal Medicine” This case report describes a patient with breast cancer who developed female androgenetic alopecia after starting tamoxifen therapy.
15 citations
,
January 1989 in “European Journal of Cancer and Clinical Oncology”
